Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.
Recently, clinical-stage biopharmaceutical company Aura Biosciences announced a Phase 2 clinical trial to determine the safety, efficacy, and tolerability of AU-011 for patients with choroidal melanoma. Currently, Aura Biosciences…
According to Ankylosing Spondylitis News, data from the Phase 3 PREVENT clinical trial highlights Cosentyx (secukinumab) as an effective treatment for patients with non-radiographic axial spondyloarthritis (nr-axSpA), as well as…
In a recent press release, biopharmaceutical company ChemoCentryx announced FDA approval for a New Drug Application (NDA) for avacopan, a treatment for ANCA-associated vasculitis. According to the FDA, a New…
Recently, pharmaceutical company Alimera Sciences announced that the first patient was enrolled in the NEW DAY clinical trial to test ILUVIEN as a potential treatment for patients with diabetic macular…
Last month, the annual ESC Congress, headed by the European Society of Cardiology, discussed innumerable treatments and advances in the field of cardiology. During the conference, biopharmaceutical company Kiniksa Pharmaceuticals…
This year, the Digital International Liver Congress took place online from August 27-29, thanks to COVID-19. During the conference, biopharmaceutical company Mirum Pharmaceuticals announced data from its Phase 2 INDIGO…
According to Charcot-Marie-Tooth News, patients with Charcot-Marie-Tooth disease type 1A (CMT1A) have an extra PMP22 gene. However, new research shows that this excess gene causes a toxic accumulation of protein within cells.…
Although we are now months into the global pandemic, new information emerges daily. Currently, COVID-19 is responsible for over 29 million cases globally, with 926,000 associated deaths. In the United…
Arguably, our entire year has been dominated by discussions of COVID-19, a novel coronavirus resulting in 28.3 million cases and 911,000 deaths across the globe. In the United States alone,…
Early this week, clinical-stage biopharmaceutical company Enterome announced that the first patient was dosed in a Phase 1/2 clinical trial. The SPENCER trial will evaluate EO2401 as a potential treatment…
According to PharmaField, the Scottish Medicines Consortium (SMC) recently approved and accepted 14 new medicines to be used by NHSScotland. Many of these medications, such as Xospata, are used to…
This past week, Target RWE announced data from its TARGET-NASH study, designed to better understand differences in health outcomes for patients with nonalcoholic fatty liver disease (NAFLD). According to their…
Caroline Wozniacki has led an interesting life. Born in Denmark, she was immediately thrust into athleticism. Her father was a former football player (that's soccer for you Americans) and her…
Last month, biotechnology company BioMarin sought approval for an investigational gene therapy (valoctocogene roxaparvovec) for patients with hemophilia A. However, their approval was denied. Instead, the company was told that…
Between August 29 and September 1, researchers joined in at ESC 2020 - The Digital Experience, developed and organized by the European Society of Cardiology (ESC). During this online conference,…
To determine the safety and efficacy of experimental gene therapy ST-920, researchers first examined the impact of the drug on mouse models of Fabry disease. As reported in Fabry Disease…
Early this week, biopharmaceutical company Avidity Biosciences announced its inclusion into a collaborative natural history study on myotonic dystrophy type 1 (DM1). The study, END-DM1, is run by the Myotonic…
To determine disease progression and severity, researchers often use biomarkers, a measurable substance that indicates disease state. According to Myasthenia Gravis News, a new study shows that acetylcholine receptor (AChR)…
Recently, biopharmaceutical company Albireo Pharma announced positive results from a Phase 3 clinical trial. The trial, PEDFIC 1, studied the safety, efficacy, and tolerability of odevixibat for patients with progressive…
According to Parkinson's News Today, Novant Health will soon become the first provider in the Carolinas to offer MR-guided focused ultrasound (MRgFUS). The therapy, with a surgery-like technique, has no…
In recent years, gene therapy has expanded to enormous heights. This experimental technique allows scientists to add, delete, edit, or otherwise use genes to address genetic malfunctions and disorders. Now,…
Recently, the MDS Foundation announced that two TP53 gene mutations result in worse patient outcomes in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). According to their international and multi center study,…
Dayton Abbott is like many kindergarteners; she loves to tell jokes, play games, and hang out with friends during recess. But her playground at Alexander Elementary School wasn't built for…
Earlier this week, the FDA approved oral azacitidine (Onureg) for patients with acute myeloid leukemia (AML). According to the ASCO Post, Onureg continuously treats adult patients who previously achieved remission.…
According to Genetic Engineering & Biotechnology News, researchers recently discovered a potential therapy for patients with aggressive subtypes of medulloblastoma. There are four subtypes of this condition. The first is…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
